Skip to main content
Erschienen in: Tumor Biology 1/2013

01.02.2013 | Research Article

Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis

verfasst von: Liangbin Xia, Jing Gao, Yan Liu, Ke Wu

Erschienen in: Tumor Biology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Recently, many studies have been published to evaluate the correlation between the cytochrome P450 1A1 (CYP1A1) T3801C polymorphism and cervical neoplasia risk. However, the results remain inconclusive. To clarify this possible association, we conducted a systematic review and meta-analysis of published studies. Data were collected from the following electronic databases: PubMed, Embase, Ovid, ISI Web of Knowledge, Google Scholar, and Chinese Biomedical Database databases. The pooled odds ratio (OR) and its 95 % confidence interval (95 % CI) were used to assess the strength of this association. The pooled ORs were performed for the allele model (C vs. T), the homozygote model (CC vs. TT), the dominant model (CC/CT vs. TT), and the recessive model (CC vs. TT/CT), respectively. Finally, a total of 12 independent studies including a total of 3,724 subjects (1,912 cases/1,812 controls) were eligible for meta-analysis. Overall, there was a significant association between the CYP1A1 T3801C polymorphism and cervical neoplasia susceptibility (C vs. T, OR 1.32, 95 % CI 1.04–1.68, P = 0.02; CC vs. TT, OR 1.99, 95 % CI 1.19–3.35, P = 0.01; CC/CT vs. TT, OR 1.36, 95 % CI 1.02–1.81, P = 0.02; CC vs. TT/CT, OR 1.57, 95 % CI 1.23–2.02, P < 0.01). Meta-analysis of the ten studies on cervical cancer suggested a significant association between the CYP1A1 T3801C polymorphism and cervical cancer risk (C vs. T, OR 1.38, 95 % CI 1.05–1.82, P = 0.02; CC vs. TT, OR 2.06, 95 % CI 1.15–3.70, P = 0.02; CC/CT vs. TT, OR 1.45, 95 % CI 1.03–2.02, P = 0.03; CC vs. TT/CT, OR 1.56, 95 % CI 1.20–2.03, P < 0.01). In the stratified analysis by ethnicity, significant associations were also detected in some genetic models. This meta-analysis demonstrates a significant association between the CYP1A1 T3801C polymorphism and cervical neoplasia susceptibility.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
3.
Zurück zum Zitat Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila). 2012;5:11–7.CrossRef Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila). 2012;5:11–7.CrossRef
4.
Zurück zum Zitat Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of pet. Lancet Oncol. 2012;13:e212–20.PubMedCrossRef Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of pet. Lancet Oncol. 2012;13:e212–20.PubMedCrossRef
5.
Zurück zum Zitat Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125:500–7.PubMedCrossRef Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125:500–7.PubMedCrossRef
6.
Zurück zum Zitat Anderson LA. Prophylactic human papillomavirus vaccines: past, present and future. Pathology. 2012;44:1–6.PubMedCrossRef Anderson LA. Prophylactic human papillomavirus vaccines: past, present and future. Pathology. 2012;44:1–6.PubMedCrossRef
7.
Zurück zum Zitat Liu D, Zhou P, Zhang L, Wu G, Zheng Y, He F. Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 2011;32:941–50.PubMedCrossRef Liu D, Zhou P, Zhang L, Wu G, Zheng Y, He F. Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 2011;32:941–50.PubMedCrossRef
8.
Zurück zum Zitat Vasilevska M, Ross SA, Gesink D, Fisman DN. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J Public Health Policy. 2012;33:148–64.PubMedCrossRef Vasilevska M, Ross SA, Gesink D, Fisman DN. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J Public Health Policy. 2012;33:148–64.PubMedCrossRef
9.
Zurück zum Zitat Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.PubMedCrossRef Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.PubMedCrossRef
10.
Zurück zum Zitat Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet. 2012;15:79–86.PubMedCrossRef Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet. 2012;15:79–86.PubMedCrossRef
11.
Zurück zum Zitat Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012. Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012.
12.
Zurück zum Zitat Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.PubMedCrossRef Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.PubMedCrossRef
13.
Zurück zum Zitat Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115–24.PubMedCrossRef Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115–24.PubMedCrossRef
14.
Zurück zum Zitat Sangar MC, Bansal S, Avadhani NG. Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2010;6:1231–51.PubMedCrossRef Sangar MC, Bansal S, Avadhani NG. Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2010;6:1231–51.PubMedCrossRef
15.
Zurück zum Zitat Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187.PubMedCrossRef Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187.PubMedCrossRef
16.
Zurück zum Zitat Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.PubMedCrossRef Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.PubMedCrossRef
17.
Zurück zum Zitat Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89–295.PubMedCrossRef Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89–295.PubMedCrossRef
18.
Zurück zum Zitat Mrozikiewicz PM, Grzeskowiak E, Seremak-Mrozikiewicz A, Bogacz A, Barlik M, Semczuk A, et al. Importance of CYP1A1 polymorphism and its transcriptional regulation in ovarian and endometrial cancer. Ginekol Pol. 2011;82:925–32.PubMed Mrozikiewicz PM, Grzeskowiak E, Seremak-Mrozikiewicz A, Bogacz A, Barlik M, Semczuk A, et al. Importance of CYP1A1 polymorphism and its transcriptional regulation in ovarian and endometrial cancer. Ginekol Pol. 2011;82:925–32.PubMed
19.
Zurück zum Zitat Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.PubMedCrossRef Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.PubMedCrossRef
20.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
21.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
22.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
23.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
24.
Zurück zum Zitat Ding FY, Ma GF, Song XH, Shi WH, Lan JY, Yu HY. Relationship between CYP1A1 gene polymorphism and genetic susceptibility of cervical carcinoma. Jiangsu Med J. 2011;37:2562–4. Ding FY, Ma GF, Song XH, Shi WH, Lan JY, Yu HY. Relationship between CYP1A1 gene polymorphism and genetic susceptibility of cervical carcinoma. Jiangsu Med J. 2011;37:2562–4.
25.
Zurück zum Zitat Shi YR, Geng J, Cheng LQ, Wang H, Zhang Y. Association of cytochrome P450 1A1 gene polymorphisms with cervical cancer. Fudan Univ J Med Sci. 2011;38:428–31. Shi YR, Geng J, Cheng LQ, Wang H, Zhang Y. Association of cytochrome P450 1A1 gene polymorphisms with cervical cancer. Fudan Univ J Med Sci. 2011;38:428–31.
26.
Zurück zum Zitat Zhang SH, Kong AR. Polymorphisms of CYP1A1 gene and HPV infection of cervical squamous carcinoma. Master’s thesis of Taishan Medical University 2009;2009 Zhang SH, Kong AR. Polymorphisms of CYP1A1 gene and HPV infection of cervical squamous carcinoma. Master’s thesis of Taishan Medical University 2009;2009
27.
Zurück zum Zitat Taskiran C, Aktas D, Yigit-Celik N, Alikasifoglu M, Yuce K, Tuncbilek E, et al. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol. 2006;101:503–6.PubMedCrossRef Taskiran C, Aktas D, Yigit-Celik N, Alikasifoglu M, Yuce K, Tuncbilek E, et al. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol. 2006;101:503–6.PubMedCrossRef
28.
Zurück zum Zitat Agorastos T, Papadopoulos N, Lambropoulos AF, Chrisafi S, Mikos T, Goulis DG, et al. Glutathione-S-transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev. 2007;16:498–504.PubMedCrossRef Agorastos T, Papadopoulos N, Lambropoulos AF, Chrisafi S, Mikos T, Goulis DG, et al. Glutathione-S-transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev. 2007;16:498–504.PubMedCrossRef
29.
Zurück zum Zitat Goodman MT, McDuffie K, Hernandez B, Bertram CC, Wilkens LR, Guo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol. 2001;81:263–9.PubMedCrossRef Goodman MT, McDuffie K, Hernandez B, Bertram CC, Wilkens LR, Guo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol. 2001;81:263–9.PubMedCrossRef
30.
Zurück zum Zitat Gutman G, Morad T, Peleg B, Peretz C, Bar-Am A, Safra T, et al. CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. Int J Gynecol Cancer. 2009;19:1300–2.PubMedCrossRef Gutman G, Morad T, Peleg B, Peretz C, Bar-Am A, Safra T, et al. CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. Int J Gynecol Cancer. 2009;19:1300–2.PubMedCrossRef
31.
Zurück zum Zitat Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol. 2006;101:411–7.PubMedCrossRef Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol. 2006;101:411–7.PubMedCrossRef
32.
Zurück zum Zitat Juarez-Cedillo T, Vallejo M, Fragoso JM, Hernandez-Hernandez DM, Rodriguez-Perez JM, Sanchez-Garcia S, et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer. 2007;43:1590–5.PubMedCrossRef Juarez-Cedillo T, Vallejo M, Fragoso JM, Hernandez-Hernandez DM, Rodriguez-Perez JM, Sanchez-Garcia S, et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer. 2007;43:1590–5.PubMedCrossRef
33.
Zurück zum Zitat Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer. 2000;88:2082–91.PubMedCrossRef Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer. 2000;88:2082–91.PubMedCrossRef
34.
Zurück zum Zitat Nishino K, Sekine M, Kodama S, Sudo N, Aoki Y, Seki N, et al. Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res. 2008;34:994–1001.PubMed Nishino K, Sekine M, Kodama S, Sudo N, Aoki Y, Seki N, et al. Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res. 2008;34:994–1001.PubMed
35.
Zurück zum Zitat Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer. 2003;13:785–90.PubMedCrossRef Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer. 2003;13:785–90.PubMedCrossRef
36.
Zurück zum Zitat von Keyserling H, Bergmann T, Schuetz M, Schiller U, Stanke J, Hoffmann C, et al. Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. Int J Gynecol Cancer. 2011;21:1664–71.CrossRef von Keyserling H, Bergmann T, Schuetz M, Schiller U, Stanke J, Hoffmann C, et al. Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. Int J Gynecol Cancer. 2011;21:1664–71.CrossRef
37.
Zurück zum Zitat Seliskar M, Rozman D. Mammalian cytochromes P450—importance of tissue specificity. Biochim Biophys Acta. 2007;1770:458–66.PubMedCrossRef Seliskar M, Rozman D. Mammalian cytochromes P450—importance of tissue specificity. Biochim Biophys Acta. 2007;1770:458–66.PubMedCrossRef
38.
Zurück zum Zitat Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a huge review. Am J Epidemiol. 2005;161:901–15.PubMedCrossRef Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a huge review. Am J Epidemiol. 2005;161:901–15.PubMedCrossRef
39.
Zurück zum Zitat Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.PubMedCrossRef Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.PubMedCrossRef
40.
Zurück zum Zitat Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32:215–22.PubMedCrossRef Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32:215–22.PubMedCrossRef
41.
Zurück zum Zitat Guo R, Guo X. Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol. 2012;33:1125–32.PubMedCrossRef Guo R, Guo X. Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol. 2012;33:1125–32.PubMedCrossRef
Metadaten
Titel
Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis
verfasst von
Liangbin Xia
Jing Gao
Yan Liu
Ke Wu
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0542-9

Weitere Artikel der Ausgabe 1/2013

Tumor Biology 1/2013 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.